The U.S. Food and Drug Administration warned on Wednesday
that the coronavirus outbreak could impact clinical trials and
recommended that companies consider conducting virtual patient visits as
the regulator looks to contain the spread of the virus.
The FDA noted that quarantines, site closures, travel limitations, supply chain interruptions, or potential infections among on-site personnel or trial participants could lead to difficulties in conducting clinical trials. (bit.ly/39WbflT)
https://www.reuters.com/article/us-health-coronavirus-fda/fda-recommends-virtual-patient-visits-to-limit-coronavirus-impact-on-clinical-trials-idUSKBN2152IP
Edit
The FDA noted that quarantines, site closures, travel limitations, supply chain interruptions, or potential infections among on-site personnel or trial participants could lead to difficulties in conducting clinical trials. (bit.ly/39WbflT)
https://www.reuters.com/article/us-health-coronavirus-fda/fda-recommends-virtual-patient-visits-to-limit-coronavirus-impact-on-clinical-trials-idUSKBN2152IP
Edit
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.